Assembly Bio reports Q1 net loss $9.1M; CTAs cleared for two clinical trials

ASSEMBLY BIOSCIENCES, INC.

Net loss narrowed to $9.1M ($1.66/sh) from $19.0M ($4.46) YoY; cash $113M funds ops into H2 2025.
CTAs cleared for Phase 1a/1b of ABI-5366 (genital herpes) and Phase 1b of ABI-4334 (HBV); both on track by mid-2024.
Interim data expected: ABI-5366 Ph1a in Q3 2024; ABI-4334 Ph1b by year-end 2024.
Two more candidates (ABI-1179 and ABI-6250) expected to enter clinic by end of 2024.
Revenue from Gilead collaboration $5.8M in Q1 2024 vs $0 prior year.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ASSEMBLY BIOSCIENCES, INC. reported first quarter ended March 31, 2024 results: revenue $5.8 million, net income $9.1 million, EPS $1.66 per basic and diluted share.

Period: first quarter ended March 31, 2024
Revenue: $5.8 million
Net income: $9.1 million
EPS: $1.66 per basic and diluted share
Result: reported results

Exact text from the filing

to $130.2 million as of December 31, 2023. Assembly Bio’s cash position is projected to fund operations into the second half of 2025. • Revenues from collaborative research were $5.8 million for the three months ended March 31, 2024. There was no revenue recognized for the same period in 2023. Revenue for the three months ended March 31, 2024 consists of amounts

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-055650

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.